Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Plamotamab · XMAB-13676, XENP13676

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and CD20 (MS4A1) · developed by Xencor

Phase 2 Most advanced trial (none active)
XNCR Developer
2 Registered trials

What is Plamotamab?

Plamotamab is a bispecific, Fc domain-containing monoclonal antibody that binds human CD3 on T cells and CD20 on B-lineage tumor cells. The cross-linking is intended to trigger a cytotoxic T-lymphocyte response against CD20-expressing B cells. It is studied in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-13676, XENP13676
Drug type
Bispecific antibody
Targets
CD3 (CD3E), CD20 (MS4A1)
Mechanism
Immune activation, directed at CD3 (CD3E) and CD20 (MS4A1)
Pathways
T-cell mediated cytotoxicity, Fc receptor binding
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5ENX424FNF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05328102 Phase 2 Diffuse Large-cell B-cell Lymphoma Terminated XNCR
NCT02924402 Phase 1 B-cell Non-Hodgkins Lymphoma Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Non-Hodgkins LymphomaChronic Lymphocytic LeukemiaDiffuse Large-cell B-cell Lymphoma

Other drugs acting on CD3E / MS4A1

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Plamotamab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.